FR18C1051I2 - Anticorps obtenus par genie genetique diriges contre l'il-23p19 - Google Patents

Anticorps obtenus par genie genetique diriges contre l'il-23p19

Info

Publication number: FR18C1051I2
Authority: FR; France
Prior art keywords: genetic; engineered antibodies; engineered; antibodies
Prior art date: 2007-02-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR18C1051C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Merck Sharp and Dohme LLC

Original Assignee

Merck Sharp and Dohme LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-02-23

Filing date

2018-12-04

Publication date

2019-12-27

2018-12-04 Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC

2019-02-15 Publication of FR18C1051I1 publication Critical patent/FR18C1051I1/fr

2019-12-27 Application granted granted Critical

2019-12-27 Publication of FR18C1051I2 publication Critical patent/FR18C1051I2/fr

Status Active legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Diabetes (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Zoology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Virology (AREA)
Ophthalmology & Optometry (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)

FR18C1051C 2007-02-23 2018-12-04 Anticorps obtenus par genie genetique diriges contre l'il-23p19 Active FR18C1051I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US89140907P	2007-02-23	2007-02-23
PCT/US2008/002333 WO2008103432A1 (fr)	2007-02-23	2008-02-21	Anticorps obtenus par génie génétique dirigés contre l'il-23p19

Publications (2)

Publication Number	Publication Date
FR18C1051I1 FR18C1051I1 (fr)	2019-02-15
FR18C1051I2 true FR18C1051I2 (fr)	2019-12-27

Family

ID=39592753

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR18C1051C Active FR18C1051I2 (fr)	2007-02-23	2018-12-04	Anticorps obtenus par genie genetique diriges contre l'il-23p19

Country Status (31)

Country	Link
US (3)	US8293883B2 (fr)
EP (2)	EP2426144B1 (fr)
JP (5)	JP2010518856A (fr)
KR (1)	KR101520110B1 (fr)
CN (1)	CN101687925B (fr)
AR (1)	AR065420A1 (fr)
AT (1)	ATE554791T1 (fr)
AU (1)	AU2008218968B2 (fr)
BR (1)	BRPI0807710B1 (fr)
CA (1)	CA2678749C (fr)
CY (3)	CY1112912T1 (fr)
DK (2)	DK2426144T3 (fr)
ES (2)	ES2388837T3 (fr)
FR (1)	FR18C1051I2 (fr)
HK (1)	HK1127864A1 (fr)
HR (2)	HRP20120611T1 (fr)
HU (2)	HUE042172T2 (fr)
IL (1)	IL200560A (fr)
LT (2)	LT2426144T (fr)
LU (1)	LUC00092I2 (fr)
MX (1)	MX2009009079A (fr)
NL (1)	NL300959I2 (fr)
NO (1)	NO2018040I1 (fr)
NZ (1)	NZ579158A (fr)
PL (2)	PL2059534T3 (fr)
PT (2)	PT2059534E (fr)
RS (2)	RS52345B (fr)
SI (2)	SI2426144T1 (fr)
TR (1)	TR201821029T4 (fr)
WO (1)	WO2008103432A1 (fr)
ZA (1)	ZA200906224B (fr)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI1896073T1 (sl)	2005-06-30	2013-06-28	Janssen Biotech, Inc.	Protitelesa proti il-23, sestavki, prostopki in uporabe
US7910703B2 (en)	2006-03-10	2011-03-22	Zymogenetics, Inc.	Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
JP5624276B2 (ja)	2006-03-31	2014-11-12	中外製薬株式会社	抗体の血中動態を制御する方法
US9028821B2 (en)	2006-06-08	2015-05-12	Chugai Seiyaku Kabushiki Kaisha	Method of treating an inflammatory disease comprising administering an NR 10 antibody antagonist
EP2044118A2 (fr)	2006-06-13	2009-04-08	Zymogenetics, Inc.	Antagonistes d'il-17 et d'il-23 et leurs procédés d'utilisation
TWI426918B (zh)	2007-02-12	2014-02-21	Merck Sharp & Dohme	Ｉｌ-２３拮抗劑於治療感染之用途
CN103396489A (zh)	2007-02-23	2013-11-20	默沙东公司	工程改造的抗IL-23p19抗体
PT2059534E (pt)	2007-02-23	2012-07-17	Schering Corp	Anticorpos anti-il-23p19 fabricados por engenharia genética
LT2769729T (lt)	2007-09-04	2019-05-10	Compugen Ltd.	Polipeptidai ir polinukleotidai ir jų panaudojimas kaip vaistų taikinio vaistų ir biologinių preparatų gamybai
US9096651B2 (en)	2007-09-26	2015-08-04	Chugai Seiyaku Kabushiki Kaisha	Method of modifying isoelectric point of antibody via amino acid substitution in CDR
ES2687808T3 (es)	2007-09-26	2018-10-29	Chugai Seiyaku Kabushiki Kaisha	Región constante de anticuerpo modificado
TW201634479A (zh)	2007-12-05	2016-10-01	Chugai Pharmaceutical Co Ltd	抗ｎｒ１０抗體及其應用
RU2596397C2 (ru)	2007-12-05	2016-09-10	Чугаи Сейяку Кабусики Кайся	Терапевтическое средство от зуда
TR201808046T4 (tr)	2008-04-11	2018-06-21	Chugai Pharmaceutical Co Ltd	İki veya daha fazla sayıda antijen molekülüne tekrar tekrar bağlanabilen antijen bağlanma molekülü.
WO2010027766A1 (fr)	2008-08-27	2010-03-11	Schering Corporation	Formulations lyophilisées d'anticorps anti-il-23p19 modifiés
CA2741566A1 (fr) *	2008-11-03	2010-06-03	Schering Corporation	Biomarqueurs de maladie inflammatoire de l'intestin et procedes apparentes du traitement
KR20160062207A (ko) *	2008-12-05	2016-06-01	추가이 세이야쿠 가부시키가이샤	항ｎｒ１０ 항체 및 그의 이용
JP5139517B2 (ja) *	2008-12-05	2013-02-06	中外製薬株式会社	抗ｎｒ１０抗体、およびその利用
US20110250644A1 (en) *	2008-12-19	2011-10-13	Schering Corporation	Feed supplement for mammalian cell culture and methods of use
KR101048593B1 (ko)	2009-02-27	2011-07-12	씨제이제일제당 (주)	메칠머캅탄과 디메칠설파이드의 혼합물을 사용하여 메치오닌 생산능을 증가시키는 방법
KR101164711B1 (ko)	2009-02-27	2012-07-11	씨제이제일제당 (주)	미네랄 첨가와 산처리를 이용하여 메치오닌의 용해도를 증가시키는 방법
JP2010210772A (ja) *	2009-03-13	2010-09-24	Dainippon Screen Mfg Co Ltd	液晶表示装置の製造方法
EP2409991B1 (fr)	2009-03-19	2017-05-03	Chugai Seiyaku Kabushiki Kaisha	Variant d'une région constante d'anticorps
TWI682995B (zh)	2009-03-19	2020-01-21	日商中外製藥股份有限公司	抗體恆定區域改變體
US20120269765A1 (en) *	2009-07-24	2012-10-25	Garcia K Christopher	Cytokine compositions and methods of use thereof
US8283152B2 (en)	2009-08-28	2012-10-09	Cj Cheiljedang Corporation	Microorganism producing O-acetyl-homoserine and the method of producing O-acetyl-homoserine using the microorganism
US8609396B2 (en)	2009-08-28	2013-12-17	Cj Cheiljedang Corporation	Microorganism producing O-acetyl-homoserine and the method of producing O-acetyl-homoserine using the microorganism
US9301997B2 (en)	2009-09-21	2016-04-05	Peptinov Sas	Method of vaccination for limiting articular inflammation in rheumatoid arthritis and multiple sclerosis by administering IL-23 peptides
JO3244B1 (ar)	2009-10-26	2018-03-08	Amgen Inc	بروتينات ربط مستضادات il – 23 البشرية
SG183215A1 (en) *	2010-02-18	2012-09-27	Bristol Myers Squibb Co	Fibronectin based scaffold domain proteins that bind il-23
MX2019000046A (es)	2010-11-04	2023-10-05	Boehringer Ingelheim Int	Anticuerpos anti-il-23.
RU2642318C2 (ru)	2010-11-30	2018-01-24	Чугаи Сейяку Кабусики Кайся	Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул
JP6077461B2 (ja)	2011-01-04	2017-02-08	ウニヴェルズィテートチューリッヒ	アルツハイマー病の予防又は治療のためのｉｌ−１２及び／又はｉｌ−２３のモジュレーター
CA2836855C (fr)	2011-06-30	2020-07-14	Compugen Ltd.	Polypeptides et leurs utilisations pour traiter les troubles auto-immuns et l'infection
EP2583979B1 (fr) *	2011-10-19	2015-12-16	Effimune	Méthodes de preparation d'anticorps dirigés contre la sous-unité p19 de l'IL-23 humaine
EP2756093A4 (fr)	2012-02-01	2015-07-01	Compugen Ltd	Anticorps de c10rf32 et leurs utilisations pour traiter le cancer
EP4039275A1 (fr) *	2012-05-03	2022-08-10	Boehringer Ingelheim International GmbH	Anticorps anti-il-23p19
ES2729603T3 (es) *	2012-06-27	2019-11-05	Merck Sharp & Dohme	Anticuerpos IL-23 antihumanos cristalinos
EP3441400B1 (fr)	2012-11-19	2022-07-20	Pieris Pharmaceuticals GmbH	Nouveaux polypeptides de liaison spécifique et leurs utilisations
CZ304514B6 (cs)	2012-11-23	2014-06-11	Biotechnologický Ústav Av Čr, V.V.I.	Polypeptidy pro léčbu autoimunitních chorob založenou na blokaci receptoru pro lidský cytokin IL-23
UA117466C2 (uk) *	2012-12-13	2018-08-10	Мерк Шарп Енд Доме Корп.	СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
WO2014093206A1 (fr) *	2012-12-13	2014-06-19	Merck Sharp & Dohme Corp.	Granulés sphériques lyophilisés d'anticorps anti-il-23
JOP20140049B1 (ar)	2013-03-08	2021-08-17	Lilly Co Eli	أجسام مضادة ترتبط بـ il-23
EP2968443B1 (fr)	2013-03-15	2021-09-29	Protagonist Therapeutics, Inc.	Analogues d'hepcidine et leurs utilisations
KR20150128859A (ko)	2013-03-15	2015-11-18	암젠 인크	항-il23 항체를 사용하여 크론병을 치료하는 방법
SG10201804954UA (en)	2013-03-15	2018-07-30	Amgen Inc	Methods for treating psoriasis using an anti-il-23 antibody
CA2949215C (fr)	2014-05-16	2023-03-14	Protagonist Therapeutics, Inc.	Antagonistes du peptide thioether .alpha.4.beta.7 integrine
WO2015177175A2 (fr)	2014-05-22	2015-11-26	Pieris Ag	Nouveaux polypeptides de liaison spécifique et utilisations associées
TWI713453B (zh)	2014-06-23	2020-12-21	美商健生生物科技公司	干擾素α及ω抗體拮抗劑
KR102482790B1 (ko)	2014-07-17	2022-12-29	프로타고니스트 테라퓨틱스, 인코포레이티드	인터루킨-23 수용체의 경구용 펩티드 억제제 및 염증성 장 질환을 치료하기 위한 그의 용도
EP3708679A1 (fr)	2014-07-24	2020-09-16	Boehringer Ingelheim International GmbH	Biomarqueurs utiles dans le traitement de maladies liées à l'il-23a
MA40475A (fr) *	2014-08-19	2017-06-28	Fayadat Dilman Laurence	Anticorps anti-tigit
EA039598B9 (ru)	2014-09-03	2022-03-10	Бёрингер Ингельхайм Интернациональ Гмбх	Соединение, нацеленное на ил-23а и фно-альфа, и его применение
MX2017004300A (es)	2014-10-01	2017-12-18	Protagonist Therapeutics Inc	ANTAGONISTAS DE MONOMÉRICOS Y DIMÉRICOS PEPTÍDICOS DE A4ß7 NOVEDOSOS.
WO2016054445A1 (fr)	2014-10-01	2016-04-07	Protagonist Therapeutics, Inc.	Nouveaux peptides monomères et dimères cycliques possédant une activité antagoniste de l'intégrine
AR102417A1 (es)	2014-11-05	2017-03-01	Lilly Co Eli	Anticuerpos biespecíficos anti-tnf- / anti-il-23
KR20170120616A (ko)	2015-02-04	2017-10-31	베링거 인겔하임 인터내셔날 게엠베하	염증성 질환의 치료 방법
EP3283109A1 (fr)	2015-04-14	2018-02-21	Boehringer Ingelheim International GmbH	Méthodes de traitement de maladies
WO2016167263A1 (fr)	2015-04-14	2016-10-20	中外製薬株式会社	Composition pharmaceutique pour la prévention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
US10787490B2 (en)	2015-07-15	2020-09-29	Protaganist Therapeutics, Inc.	Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA2998349A1 (fr)	2015-09-17	2017-03-23	Amgen Inc.	Prediction de reponse clinique a des antagonistes d'il23 utilisant des biomarqueurs de la voie de l'il23
TWI733695B (zh)	2015-09-18	2021-07-21	德商百靈佳殷格翰國際股份有限公司	治療發炎性疾病之方法
AU2016379157A1 (en)	2015-12-22	2018-06-21	Amgen Inc.	CCL20 as a predictor of clinical response to IL23-antagonists
CA3009834A1 (fr)	2015-12-30	2017-07-06	Protagonist Therapeutics, Inc.	Analogues de mimetiques d'hepcidine a demi-vie in vivo amelioree
CA3017926C (fr)	2016-03-23	2023-10-10	Protagonist Therapeutics, Inc.	Procedes de synthese d'antagonistes de peptide .alpha.4.beta.7
EP3974451A3 (fr)	2016-04-15	2022-07-06	Boehringer Ingelheim International GmbH	Procédés de traitement de maladies inflammatoires
WO2018071455A1 (fr)	2016-10-10	2018-04-19	Cellerant Therapeutics, Inc.	Dimères d'isoquinolidinobenzodiazépine (iqb)-1(chlorométhyl)-2,3-dihydro-1h-benzo[e]indole (cbi)
EP3677597A1 (fr)	2016-10-14	2020-07-08	Boehringer Ingelheim International GmbH	Procédés de traitement de maladies
AU2017343784A1 (en)	2016-10-16	2019-08-29	Cantargia Ab	Anti-IL1-RAP antibodies
WO2018071910A2 (fr) *	2016-10-16	2018-04-19	Cellerant Therapeutics, Inc.	Anticorps anti-il1-rap
JOP20190260A1 (ar)	2017-05-02	2019-10-31	Merck Sharp & Dohme	صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
SG11201909955XA (en)	2017-05-02	2019-11-28	Merck Sharp & Dohme	Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
CA3073806A1 (fr)	2017-09-11	2019-03-14	Protagonist Therapeutics, Inc.	Peptides d'agoniste opioide et leurs utilisations
EP3749345A4 (fr)	2018-02-08	2022-04-06	Protagonist Therapeutics, Inc.	Mimétiques d'hepcidine conjugués
TWI837532B (zh)	2018-03-30	2024-04-01	美商美國禮來大藥廠	治療潰瘍性結腸炎之方法
AU2019300491A1 (en)	2018-07-13	2021-03-04	Astrazeneca Collaboration Ventures, Llc	Treating ulcerative colitis with brazikumab
KR20210096559A (ko) *	2018-11-27	2021-08-05	이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드	항IL-23p19 항체 및 이의 용도
EP3952993A1 (fr)	2019-04-12	2022-02-16	Almirall S.A.	Procédé de traitement du psoriasis en plaques résistant aux esters d'acide fumarique
CA3143604A1 (fr) *	2019-04-15	2020-10-22	Sun Pharmaceutical Industries Limited	Procedes de traitement de sujets atteints d'arthrite psoriasique
EP3997105A4 (fr)	2019-07-10	2023-09-13	Protagonist Therapeutics, Inc.	Inhibiteurs peptidiques du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires
EP4062933A4 (fr)	2019-11-20	2023-12-13	Chugai Seiyaku Kabushiki Kaisha	Préparation pharmaceutique comprenant un anticorps
KR20220143005A (ko)	2019-12-20	2022-10-24	노바록 바이오테라퓨틱스 리미티드	항-인터루킨-23 p19 항체 및 이의 사용 방법
TW202140517A (zh)	2020-01-15	2021-11-01	美商健生生物科技公司	介白素-23受體之肽抑制劑及其治療發炎性疾病之用途
CN115279782A (zh)	2020-01-15	2022-11-01	詹森生物科技公司	白介素-23受体的肽抑制剂及其用于治疗炎性疾病的用途
KR102481026B1 (ko) *	2020-04-22	2022-12-22	한양대학교 산학협력단	인터루킨 23의 항체를 포함하는 화학요법유발 말초신경병증의 예방 또는 치료용 약학적 조성물
CN111718414B (zh) *	2020-06-12	2021-03-02	江苏荃信生物医药有限公司	抗人白介素23单克隆抗体及其应用
TW202224702A (zh)	2020-09-10	2022-07-01	美商美國禮來大藥廠	治療性抗體調配物
EP4247403A1 (fr)	2020-11-20	2023-09-27	JANSSEN Pharmaceutica NV	Compositions d'inhibiteurs peptidiques du récepteur de l'interleukine-23
WO2022251623A1 (fr)	2021-05-28	2022-12-01	Eli Lilly And Company	Régulation d'anticorps anti-il-23p19 de gènes impliqués dans la rectocolite hémorragique
WO2023056417A1 (fr)	2021-09-30	2023-04-06	Eli Lilly And Company	Régulation d'anticorps anti-il-23p19 de gènes impliqués dans l'urgence intestinale dans la colite ulcéreuse
JP2024536870A (ja) *	2021-09-30	2024-10-08	江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司	抗ｉｌ２３抗体融合タンパク質及び使用
IL314265A (en) *	2022-01-25	2024-09-01	Sun Pharmaceutical Ind Ltd	Methods for treating subjects with plaque psoriasis on the scalp
WO2024077113A1 (fr)	2022-10-06	2024-04-11	Eli Lilly And Company	Méthodes de traitement de la fatigue liée à la colite ulcéreuse
WO2024178157A1 (fr)	2023-02-22	2024-08-29	Eli Lilly And Company	Régulation de gènes dans la colite ulcéreuse et leurs utilisations

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL154598B (nl)	1970-11-10	1977-09-15	Organon Nv	Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en)	1971-05-14	1974-06-18	Syva Corp	Enzyme amplification assay
US3939350A (en)	1974-04-29	1976-02-17	Board Of Trustees Of The Leland Stanford Junior University	Fluorescent immunoassay employing total reflection for activation
US3996345A (en)	1974-08-12	1976-12-07	Syva Company	Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en)	1978-04-05	1981-07-07	Syva Company	Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en)	1978-11-24	1981-06-23	Syva Company	Macromolecular environment control in specific receptor assays
US4366241A (en)	1980-08-07	1982-12-28	Syva Company	Concentrating zone method in heterogeneous immunoassays
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
AU600575B2 (en)	1987-03-18	1990-08-16	Sb2, Inc.	Altered antibodies
AU634186B2 (en)	1988-11-11	1993-02-18	Medical Research Council	Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0438310A1 (fr)	1990-01-19	1991-07-24	Merck & Co. Inc.	Méthode de production d'immunoglobulines recombinantes
EP1136556B1 (fr)	1991-11-25	2005-06-08	Enzon, Inc.	Procédé pour produire de protéines multivalents de fixation de l'antigène
US6096289A (en) *	1992-05-06	2000-08-01	Immunomedics, Inc.	Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
PT1621554E (pt)	1992-08-21	2009-07-13	Univ Bruxelles	Imunoglobtainas desprovidas de cadeias leves
US6005079A (en)	1992-08-21	1999-12-21	Vrije Universiteit Brussels	Immunoglobulins devoid of light chains
DK0698097T3 (da)	1993-04-29	2001-10-08	Unilever Nv	Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
WO1997003715A1 (fr)	1995-07-21	1997-02-06	The General Hospital Corporation	Procede et appareil permettant de faciliter l'administration d'une preparation pharmaceutique
US6060284A (en) *	1997-07-25	2000-05-09	Schering Corporation	DNA encoding interleukin-B30
ATE474849T1 (de) *	1998-04-14	2010-08-15	Chugai Pharmaceutical Co Ltd	Neues cytokinartiges protein
US6326482B1 (en)	1999-04-23	2001-12-04	Genentech, Inc.	SH2 domain-containing peptides
ATE420894T1 (de)	1999-03-11	2009-01-15	Schering Corp	Cytokine aus säugetieren, verwandte reagenzien und verfahren
CA2388562C (fr)	1999-09-09	2014-07-22	Schering Corporation	Cytokines de mammifere : reactifs et procedes associes
US7090847B1 (en) *	1999-09-09	2006-08-15	Schering Corporation	Mammalian cytokines; related reagents and methods
US7422743B2 (en) *	2000-05-10	2008-09-09	Schering Corporation	Mammalian receptor protein DCRS5;methods of treatment
AR039067A1 (es) *	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
US20040014194A1 (en)	2002-03-27	2004-01-22	Schering Corporation	Beta-secretase crystals and methods for preparing and using the same
WO2003086310A2 (fr)	2002-04-12	2003-10-23	Ramot At Tel Aviv University Ltd.	Prevention de l'inflammation du cerveau en tant que resultat d'une reponse auto-immune induite
JP5477998B2 (ja)	2002-10-30	2014-04-23	ジェネンテック，インコーポレイテッド	Ｉｌ−１７産生の阻害
US20040219150A1 (en)	2003-02-06	2004-11-04	Cua Daniel J.	Uses of mammalian cytokine; related reagents
NZ541898A (en)	2003-03-10	2008-07-31	Schering Corp	Uses of IL-23 antagonists for the manufacture of a medicament for the treatment of tumors
US7410483B2 (en)	2003-05-23	2008-08-12	Novare Surgical Systems, Inc.	Hand-actuated device for remote manipulation of a grasping tool
WO2005044853A2 (fr)	2003-11-01	2005-05-19	Genentech, Inc.	Anticorps anti-vegf
CN1871359B (zh)	2003-10-22	2010-11-17	凯克研究生院	使用单倍体交配策略在酵母中合成异聚多亚基多肽的方法
EP1697417A2 (fr)	2003-11-07	2006-09-06	Curagen Corporation	Anticorps diriges contre l'inhibiteur de la protease des leucocytes secreteurs
WO2005047324A2 (fr)	2003-11-10	2005-05-26	Schering Corp	Anticorps anti-interleukine-10
EP1766396B1 (fr)	2004-06-07	2010-08-11	Ramot at Tel-Aviv University Ltd.	Procede d'immunisation passive contre des maladies ou des troubles caracterise(e)s par agregation amyloide a risque diminue de neuroinflammation
AR049390A1 (es) *	2004-06-09	2006-07-26	Wyeth Corp	Anticuerpos contra la interleuquina-13 humana y usos de los mismos
WO2006068987A2 (fr) *	2004-12-20	2006-06-29	Schering Corporation	Utilisations de cytokine mammalienne, reactifs associes
PT1850873T (pt) *	2005-02-08	2019-02-19	Genzyme Corp	Anticorpos contra tgfbeta
SI1896073T1 (sl) *	2005-06-30	2013-06-28	Janssen Biotech, Inc.	Protitelesa proti il-23, sestavki, prostopki in uporabe
PT1937721E (pt)	2005-08-25	2010-09-17	Lilly Co Eli	Anticorpos anti-il-23
EP2354160A1 (fr) *	2005-08-31	2011-08-10	Schering Corporation	Synthèse d'anticorps anti-IL-23
MY162559A (en)	2005-12-29	2017-06-15	Centocor Inc	Human anti-il-23 antibodies, compositions, methods and uses
EP2044118A2 (fr) *	2006-06-13	2009-04-08	Zymogenetics, Inc.	Antagonistes d'il-17 et d'il-23 et leurs procédés d'utilisation
CN103396489A (zh)	2007-02-23	2013-11-20	默沙东公司	工程改造的抗IL-23p19抗体
PT2059534E (pt)	2007-02-23	2012-07-17	Schering Corp	Anticorpos anti-il-23p19 fabricados por engenharia genética
ES2465223T3 (es)	2007-04-27	2014-06-05	Zymogenetics, Inc.	Antagonistas de IL-17A, IL-17F e IL-23P19 y procedimientos de uso
AR068723A1 (es) *	2007-10-05	2009-12-02	Glaxo Group Ltd	Proteina que se une a antigenos que se une a il-23 humana y sus usos
EP2215123A1 (fr)	2007-11-27	2010-08-11	Ablynx N.V.	Constructions d'immunoglobuline
WO2009082624A2 (fr)	2007-12-10	2009-07-02	Zymogenetics, Inc.	Antagonistes de il-17a, il-17f et il-23 et procédés d'utilisation de ceux-ci

2008
- 2008-02-21 PT PT08714211T patent/PT2059534E/pt unknown
- 2008-02-21 NZ NZ579158A patent/NZ579158A/en unknown
- 2008-02-21 CA CA2678749A patent/CA2678749C/fr active Active
- 2008-02-21 ES ES08714211T patent/ES2388837T3/es active Active
- 2008-02-21 HU HUE11172014A patent/HUE042172T2/hu unknown
- 2008-02-21 CN CN2008800131689A patent/CN101687925B/zh active Active
- 2008-02-21 WO PCT/US2008/002333 patent/WO2008103432A1/fr active Application Filing
- 2008-02-21 RS RS20120308A patent/RS52345B/en unknown
- 2008-02-21 DK DK11172014.0T patent/DK2426144T3/en active
- 2008-02-21 SI SI200832032T patent/SI2426144T1/sl unknown
- 2008-02-21 BR BRPI0807710-0A patent/BRPI0807710B1/pt active IP Right Grant
- 2008-02-21 PT PT11172014T patent/PT2426144T/pt unknown
- 2008-02-21 AU AU2008218968A patent/AU2008218968B2/en active Active
- 2008-02-21 MX MX2009009079A patent/MX2009009079A/es active IP Right Grant
- 2008-02-21 DK DK08714211.3T patent/DK2059534T3/da active
- 2008-02-21 TR TR2018/21029T patent/TR201821029T4/tr unknown
- 2008-02-21 PL PL08714211T patent/PL2059534T3/pl unknown
- 2008-02-21 EP EP11172014.0A patent/EP2426144B1/fr active Active
- 2008-02-21 AT AT08714211T patent/ATE554791T1/de active
- 2008-02-21 PL PL11172014T patent/PL2426144T3/pl unknown
- 2008-02-21 RS RS20181559A patent/RS58098B1/sr unknown
- 2008-02-21 SI SI200830700T patent/SI2059534T1/sl unknown
- 2008-02-21 JP JP2009550920A patent/JP2010518856A/ja active Pending
- 2008-02-21 EP EP08714211A patent/EP2059534B1/fr active Active
- 2008-02-21 ES ES11172014T patent/ES2708988T3/es active Active
- 2008-02-21 AR ARP080100715A patent/AR065420A1/es active IP Right Grant
- 2008-02-21 KR KR1020097019349A patent/KR101520110B1/ko active IP Right Grant
- 2008-02-21 US US12/526,543 patent/US8293883B2/en active Active
- 2008-02-21 LT LTEP11172014.0T patent/LT2426144T/lt unknown
2009
- 2009-06-11 HK HK09105259.6A patent/HK1127864A1/xx unknown
- 2009-08-23 IL IL200560A patent/IL200560A/en active Protection Beyond IP Right Term
- 2009-09-08 ZA ZA200906224A patent/ZA200906224B/xx unknown
2011
- 2011-02-21 US US13/031,544 patent/US8404813B2/en active Active
2012
- 2012-03-07 JP JP2012050650A patent/JP5014521B2/ja active Active
- 2012-07-10 JP JP2012154567A patent/JP2012228259A/ja active Pending
- 2012-07-20 CY CY20121100644T patent/CY1112912T1/el unknown
- 2012-07-24 HR HRP20120611AT patent/HRP20120611T1/hr unknown
- 2012-12-17 US US13/717,131 patent/US9809648B2/en active Active
2014
- 2014-02-27 JP JP2014036399A patent/JP6054898B2/ja active Active
2016
- 2016-10-27 JP JP2016210272A patent/JP2017060482A/ja not_active Withdrawn
2018
- 2018-11-09 HU HUS1800045C patent/HUS1800045I1/hu unknown
- 2018-11-13 LU LU00092C patent/LUC00092I2/fr unknown
- 2018-11-15 NO NO2018040C patent/NO2018040I1/no unknown
- 2018-12-04 FR FR18C1051C patent/FR18C1051I2/fr active Active
- 2018-12-05 NL NL300959C patent/NL300959I2/en unknown
- 2018-12-13 LT LTPA2018015C patent/LTC2059534I2/lt unknown
- 2018-12-21 HR HRP20182174TT patent/HRP20182174T1/hr unknown
2019
- 2019-01-14 CY CY2019004C patent/CY2019004I2/el unknown
- 2019-01-21 CY CY20191100082T patent/CY1121327T1/el unknown

Also Published As

Publication number	Publication date
US20110142853A1 (en)	2011-06-16
CY1121327T1 (el)	2020-05-29
DK2426144T3 (en)	2019-01-07
LUC00092I1 (fr)	2018-11-15
HK1127864A1 (fr)	2009-10-09
MX2009009079A (es)	2009-08-31
IL200560A0 (en)	2010-05-17
AU2008218968B2 (en)	2013-10-17
NO2018040I1 (no)	2018-11-15
US8293883B2 (en)	2012-10-23
IL200560A (en)	2013-11-28
WO2008103432A1 (fr)	2008-08-28
CN101687925A (zh)	2010-03-31
US20130122009A1 (en)	2013-05-16
JP2010518856A (ja)	2010-06-03
DK2059534T3 (da)	2012-08-06
ES2708988T3 (es)	2019-04-12
CA2678749A1 (fr)	2008-08-28
HUS1800045I1 (hu)	2018-12-28
SI2426144T1 (sl)	2019-02-28
CY2019004I1 (el)	2019-11-27
HUE042172T2 (hu)	2019-06-28
PL2426144T3 (pl)	2019-05-31
BRPI0807710B1 (pt)	2021-12-14
JP6054898B2 (ja)	2016-12-27
BRPI0807710A8 (pt)	2016-02-10
KR101520110B1 (ko)	2015-05-18
ZA200906224B (en)	2010-07-28
KR20090114459A (ko)	2009-11-03
FR18C1051I1 (fr)	2019-02-15
PL2059534T3 (pl)	2012-09-28
LTPA2018015I1 (lt)	2019-01-10
AU2008218968A1 (en)	2008-08-28
PT2059534E (pt)	2012-07-17
RS52345B (en)	2012-12-31
LTC2059534I2 (lt)	2019-10-10
BRPI0807710A2 (pt)	2014-05-27
CN101687925B (zh)	2012-10-31
EP2426144A1 (fr)	2012-03-07
AR065420A1 (es)	2009-06-03
ES2388837T3 (es)	2012-10-19
EP2059534A1 (fr)	2009-05-20
HRP20120611T1 (hr)	2012-10-31
EP2426144B1 (fr)	2018-10-31
US20100272731A1 (en)	2010-10-28
CY1112912T1 (el)	2016-04-13
NZ579158A (en)	2012-01-12
CA2678749C (fr)	2018-03-13
RS58098B1 (sr)	2019-02-28
PT2426144T (pt)	2019-02-06
ATE554791T1 (de)	2012-05-15
JP2017060482A (ja)	2017-03-30
JP2012228259A (ja)	2012-11-22
NL300959I2 (en)	2019-01-15
JP2014128278A (ja)	2014-07-10
LUC00092I2 (fr)	2019-12-24
JP2012135319A (ja)	2012-07-19
SI2059534T1 (sl)	2012-08-31
JP5014521B2 (ja)	2012-08-29
TR201821029T4 (tr)	2019-01-21
US8404813B2 (en)	2013-03-26
US9809648B2 (en)	2017-11-07
EP2059534B1 (fr)	2012-04-25
LT2426144T (lt)	2018-12-10
HRP20182174T1 (hr)	2019-02-22
CY2019004I2 (el)	2019-11-27

Publication	Publication Date	Title
FR18C1051I2 (fr)	2019-12-27	Anticorps obtenus par genie genetique diriges contre l'il-23p19
FR21C1040I1 (fr)	2021-11-19	Formulations d'anticorps anti-cd20
BRPI0814252A2 (pt)	2015-04-14	Formulações de anticorpo
NO20093032L (no)	2009-10-22	Topiske formuleringer med økt biotilgjengelighet
BRPI0922904A2 (pt)	2018-05-29	"compostos"
BRPI0914375A2 (pt)	2015-10-20	''composições antiperspirantes''
ATE530578T1 (de)	2011-11-15	Antikörper gegen il-17a
BRPI0916123A2 (pt)	2015-11-03	"composição de xampu concentrada"
MA30948B1 (fr)	2009-12-01	MYRTILLE NOMME " DrisBlueThree "
BRPI0910229A2 (pt)	2015-09-01	Tetramatos de 4';4'-dioxaspiro espirociclicamente substituídos
BRPI0906877A2 (pt)	2015-07-28	Anticorpos anti-trkb aperfeiçoados
DK3072906T3 (da)	2021-12-13	Antistofformulering
BRPI0907237A2 (pt)	2015-07-14	Anticorpo anti-cldn6
MA30949B1 (fr)	2009-12-01	MYRTILLE NOMME "DrisBlueTwo"
BRPI0914346A2 (pt)	2015-10-20	''composição antiperspirante anidra''
BRPI0906055A2 (pt)	2015-06-30	"embalagem refechável"
DK3608330T3 (da)	2023-02-06	Syntetiske mellemprodukter til fremstilling af oligosaccharid-protein-konjugater
BRPI0914533A2 (pt)	2015-12-15	"métodos"
BRPI0817427A2 (pt)	2015-06-16	Anticorpo anti-bst2
BRPI0914503A2 (pt)	2016-01-12	"composição de shampoo concentrado"
BRPI0909633A2 (pt)	2015-09-22	anticorpos anti-tyrp1
BRPI0815332A2 (pt)	2015-02-10	Composto de ácido fenilacético
BRPI0907062A2 (pt)	2015-07-07	"hidrociclone"
ITMI20080346A1 (it)	2009-09-01	"dispositivo di frenatura"
FR2922212B1 (fr)	2011-11-11	Anticorps anti ricine